New hope for Tough-to-Treat head and neck cancers
NCT ID NCT07136545
Summary
This study is testing whether adding an experimental drug called HCB101 to an existing immunotherapy (pembrolizumab) can help control advanced head and neck cancer that has returned or spread and stopped responding to standard platinum-based chemotherapy. The trial will enroll about 50 adults to first find a safe dose and then see how well the combination works at shrinking tumors and improving quality of life. Participants will receive weekly infusions of HCB101 along with pembrolizumab every three weeks until the cancer progresses or side effects become too severe.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HNSCC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chang-Gung Memorial Hospital(Lin-Kou)
RECRUITINGTaoyuan District, Guishan District, 333, Taiwan
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
National Taiwan University Hospital
RECRUITINGTaipei, Taipei city, 100, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Taipei Veterans General Hospital
RECRUITINGTaipei, taipei city, 112, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.